Tandem24
The novel DuplexSeq AML-XP next-generation sequencing assay was highly accurate for detecting MRD in AML.
53.8% of patients treated with blinatumomab achieved MRD negativity within a median of 3.1 months, as detected with clonoSEQ.
Patients with LBCL who received CAR T-cell therapy earlier in treatment had lower occurrences of severe neutropenia.
Advertisement
The study used public data from various online sources related to approved CAR-T therapies for MM.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.